Factor XIII - CSL Behring

Drug Profile

Factor XIII - CSL Behring

Alternative Names: Blood coagulation factor XIII - CSL Behring; Coagulation factor XIII - CSL Behring; Corifact; Fibrin stabilising factor - CSL Behring; Fibrogammin-P

Latest Information Update: 19 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CSL Behring
  • Developer CSL Behring; University College London
  • Class Antihaemorrhagics; Blood coagulation factors
  • Mechanism of Action Factor XIII stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Factor XIII deficiency
  • New Molecular Entity No

Highest Development Phases

  • Marketed Factor XIII deficiency; Surgical blood loss
  • Phase II Systemic scleroderma

Most Recent Events

  • 28 Feb 2013 Launched for Surgical blood loss in USA (IV)
  • 28 Feb 2013 Registered for Surgical blood loss in USA (IV)
  • 31 Aug 2011 CSL Behring completes a phase III trial in Factor XIII deficiency in USA (NCT00945906)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top